Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
ESMO Real World Data and Digital Oncology|February 6, 2026
Core variables for real-world clinicogenomic data collection in precision oncologyR Dienstmann, A Hackshaw, J-Y Blay, et al.
ESMO Real World Data and Digital Oncology|April 3, 2026
AI assistance in tumor multidisciplinary teamsR J Geukes Foppen, M Morkūnas, A Traverso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 23, 2013
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumorsR Dienstmann, J Rodon, A Prat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2018
CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancerJ Smeby, A Sveen, M A Merok, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 21, 2020
Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patientsA Hernando-Calvo, A García-Alvarez, G Villacampa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancerR Dienstmann, G Villacampa, A Sveen, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinationsJ Ros, V Navarro, G Villacampa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2014
Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trialJ Bines, R Dienstmann, R M Obadia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2020
Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancerG Serna, F Ruiz-Pace, J Hernando, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patientsF Salvà, G Catani, N Saoudi, et al.
Pageof 3